Log in

LON:GNSGenus Share Price, Forecast & News

GBX 3,424
-30.00 (-0.87 %)
(As of 08/11/2020 04:52 AM ET)
Today's Range
Now: GBX 3,424
50-Day Range
MA: GBX 3,474.88
52-Week Range
Now: GBX 3,424
Volume84,947 shs
Average Volume78,154 shs
Market Capitalization£2.23 billion
P/E Ratio59.44
Dividend Yield0.83%
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers; and agricultural and agri-food consultancy services. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom.
Read More
Genus logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.7Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales£520.40 million
Cash FlowGBX 47.48 per share
Book ValueGBX 764.60 per share



Market Cap£2.23 billion
Next Earnings Date9/8/2020 (Estimated)
OptionableNot Optionable
GBX 3,424
-30.00 (-0.87 %)
(As of 08/11/2020 04:52 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNS News and Ratings via Email

Sign-up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Genus (LON:GNS) Frequently Asked Questions

How has Genus' stock been impacted by COVID-19 (Coronavirus)?

Genus' stock was trading at GBX 3,472 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GNS shares have decreased by 1.4% and is now trading at GBX 3,424.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Genus?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Genus

When is Genus' next earnings date?

Genus is scheduled to release its next quarterly earnings announcement on Tuesday, September 8th 2020.
View our earnings forecast for Genus

How often does Genus pay dividends? What is the dividend yield for Genus?

Genus declared a dividend on Thursday, February 27th. Stockholders of record on Thursday, March 5th will be given a dividend of GBX 9.40 per share on Thursday, April 2nd. This represents a yield of 0.3%. The ex-dividend date is Thursday, March 5th. The official announcement can be seen at this link.
View Genus' dividend history

What price target have analysts set for GNS?

5 brokerages have issued 12-month target prices for Genus' shares. Their forecasts range from GBX 3,200 to GBX 4,120. On average, they anticipate Genus' share price to reach GBX 3,468.40 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price.
View analysts' price targets for Genus

Has Genus been receiving favorable news coverage?

News coverage about GNS stock has trended somewhat negative on Tuesday, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genus earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Genus

Who are some of Genus' key competitors?

What other stocks do shareholders of Genus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco Plc Ads (BATS), Cronos Group (CRON), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE) and Experian (EXPN).

Who are Genus' key executives?

Genus' management team includes the following people:
  • Mr. Karim Bitar, CEO & Exec. Director (Age 54)
  • Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 59)
  • Dr. Jonathan Lightner, Chief of R&D and Scientific Officer
  • Mr. Dan Hartley, Group Gen. Counsel & Company Sec.
  • Ms. Angelle R. Rosata, Group HR Director

What is Genus' stock symbol?

Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS."

How do I buy shares of Genus?

Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Genus' stock price today?

One share of GNS stock can currently be purchased for approximately GBX 3,424.

How big of a company is Genus?

Genus has a market capitalization of £2.23 billion and generates £520.40 million in revenue each year. Genus employs 2,900 workers across the globe.

What is Genus' official website?

The official website for Genus is www.genusplc.com.

How can I contact Genus?

Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.